Updated: WuXi AppTec to divest clinical services in China to focus on manufacturing business
更新：药明康德将剥离其在manbetx3.0 的临床服务，专注制造业务

As WuXi AppTec’s manufacturing revenue recovers, it said it is selling its clinical research services business in China to a Singapore-headquartered private equity firm.
药明康德的制造业务收入正在复苏之际，该公司表示正将其在manbetx3.0 的临床研究服务业务出售给一家总部位于新加坡的私募股权公司。